A YAP/TAZ-regulated molecular signature is associated with Oral squamous cell carcinoma

Molecular Cancer Research

Volumn 13, Issue 6, 2015, Pages 957-968

  Hiemer, Samantha E ^a   Zhang, Liye ^a   Kartha, Vinay K ^a,b   Packer, Trevor S ^b   Almershed, Munirah ^b   Noonan, Vikki ^b   Kukuruzinska, Maria ^b   Bais, Manish V ^b   Monti, Stefano ^a   Varelas, Xaralabos ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAZ; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; ORAL CANCER CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CARCINOGENESIS; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUTH TUMOR; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; ULTRASTRUCTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MOUTH NEOPLASMS; PHOSPHOPROTEINS; TRANSCRIPTION FACTORS;

EID: 84942307151     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0580     Document Type: Article

References (46)

1. Varelas X, Kukuruzinska MA. Head and neck cancer: from research to therapy and cure. Ann N Y Acad Sci 2014;1333:1-32.
2. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013;13:246-57.
3. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001;15:1229-41.
4. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22:1962-71.
5. Camargo FD, Gokhale S, Johnnidis JB, Fu D, BellGW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007;17:2054-60.
6. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008;68:2592-8.
7. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-33.
8. Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 2014;141:1614-26.
9. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. Embo J 2000;19:6778-91.
10. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev 2010;24:72-85.
11. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 2014;94:1287-312.
12. Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell Biol 2012;22:339-46.
13. Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, SudolM, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011;32:389-98.
14. Wei Z, Wang Y, Li Z, Yuan C, Zhang W, Wang D, et al. Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients' prognosis. J Oral Pathol Med 2013;42:747-54.
15. Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan KH, et al. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS ONE 2011;6:e27529.
16. Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, et al. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 2010;70:8517-25.
17. Jerhammar F, Johansson AC, Ceder R, Welander J, Jansson A, Grafstrom RC, et al. YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral Oncol 2014;50:832-9.
18. Schmitz S, Ang KK, Vermorken J, Haddad R, Suarez C, Wolf GT, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev 2014;40:390-404.
19. Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, Amornphimoltham P, et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 2011;71:7103-12.
20. Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem 2014;289:13461-74.
21. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003;9:493-501.
22. Jamal B, Sengupta PK, Gao ZN, Nita-Lazar M, Amin B, Jalisi S, et al. Aberrant amplification of the crosstalk between canonical Wnt signaling and Nglycosylation gene DPAGT1 promotes oral cancer. Oral Oncol 2012;48:523-9.
23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
24. DaiM, Wang P, Boyd AD, KostovG, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:e175.
25. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27:1739-40.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
27. Ehsanian R, Brown M, Lu H, Yang XP, Pattatheyil A, Yan B, et al. YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 2010;29:6160-71.
28. Zhang L, Ye DX, Pan HY, Wei KJ, Wang LZ, Wang XD, et al. Yes-associated protein promotes cell proliferation by activating Fos Related Activator-1 in oral squamous cell carcinoma. Oral Oncol 2011;47:693-7.
29. Dong G, Loukinova E, Chen Z, Gangi L, Chanturita TI, Liu ET, et al. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res 2001;61:4797-808.
30. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003;11:11-23.
31. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-61.
32. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011;147:759-72.
33. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011;144:782-95.
34. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev Cell 2010;19:831-44.
35. Nita-Lazar M, Noonan V, Rebustini I, Walker J, Menko AS, Kukuruzinska MA. Overexpression of DPAGT1 leads to aberrant N-glycosylation of Ecadherin and cellular discohesion in oral cancer. Cancer Res 2009;69:5673-80.
36. Mahoney JE, Mori M, Szymaniak AD, Varelas X, Cardoso WV. The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. Dev Cell 2014;30:137-50.
37. Zhao R, Fallon TR, Saladi SV, Pardo-Saganta A, Villoria J, Mou H, et al. Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. Dev Cell 2014;30:151-65.
38. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 2012;109:E2441-50.
39. Chen GS, Chen CH. [A study on survival rates of oral squamous cell carcinoma]. Kaohsiung J Med Sci 1996;12:317-25.
40. Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway. Biochim Biophys Acta 2013;1830:2323-34.
41. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008;10:837-48.
42. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 2014;158:157-70.
43. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, et al. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 2010;18:579-91.
44. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
45. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res 2014;74:4170-82.
46. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 2009;284:14347-58.